Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 963

3.

The JAK-inhibitor, JAB/SOCS-1 selectively inhibits cytokine-induced, but not v-Src induced JAK-STAT activation.

Iwamoto T, Senga T, Naito Y, Matsuda S, Miyake Y, Yoshimura A, Hamaguchi M.

Oncogene. 2000 Sep 28;19(41):4795-801.

5.

SOCS-3 is frequently methylated in head and neck squamous cell carcinoma and its precursor lesions and causes growth inhibition.

Weber A, Hengge UR, Bardenheuer W, Tischoff I, Sommerer F, Markwarth A, Dietz A, Wittekind C, Tannapfel A.

Oncogene. 2005 Oct 6;24(44):6699-708.

PMID:
16007169
6.

Epigallocatechin-3-gallate decreases VEGF production in head and neck and breast carcinoma cells by inhibiting EGFR-related pathways of signal transduction.

Masuda M, Suzui M, Lim JT, Deguchi A, Soh JW, Weinstein IB.

J Exp Ther Oncol. 2002 Nov-Dec;2(6):350-9.

PMID:
12440226
7.

Constitutional activation of IL-6-mediated JAK/STAT pathway through hypermethylation of SOCS-1 in human gastric cancer cell line.

To KF, Chan MW, Leung WK, Ng EK, Yu J, Bai AH, Lo AW, Chu SH, Tong JH, Lo KW, Sung JJ, Chan FK.

Br J Cancer. 2004 Oct 4;91(7):1335-41.

8.

Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches.

Lai SY, Johnson FM.

Drug Resist Updat. 2010 Jun;13(3):67-78. doi: 10.1016/j.drup.2010.04.001. Epub 2010 May 14. Review.

PMID:
20471303
9.
10.

Resveratrol inhibits STAT3 signaling pathway through the induction of SOCS-1: Role in apoptosis induction and radiosensitization in head and neck tumor cells.

Baek SH, Ko JH, Lee H, Jung J, Kong M, Lee JW, Lee J, Chinnathambi A, Zayed ME, Alharbi SA, Lee SG, Shim BS, Sethi G, Kim SH, Yang WM, Um JY, Ahn KS.

Phytomedicine. 2016 May 15;23(5):566-77. doi: 10.1016/j.phymed.2016.02.011. Epub 2016 Feb 27.

PMID:
27064016
13.

A SOCS-1 peptide mimetic inhibits both constitutive and IL-6 induced activation of STAT3 in prostate cancer cells.

Flowers LO, Subramaniam PS, Johnson HM.

Oncogene. 2005 Mar 17;24(12):2114-20.

PMID:
15688010
14.

Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation.

Kim SM, Kwon OJ, Hong YK, Kim JH, Solca F, Ha SJ, Soo RA, Christensen JG, Lee JH, Cho BC.

Mol Cancer Ther. 2012 Oct;11(10):2254-64. doi: 10.1158/1535-7163.MCT-12-0311. Epub 2012 Aug 13.

15.
16.

SOCS 3 and PPAR-gamma ligands inhibit the expression of IL-6 and TGF-beta1 by regulating JAK2/STAT3 signaling in pancreas.

Yu JH, Kim KH, Kim H.

Int J Biochem Cell Biol. 2008;40(4):677-88. Epub 2007 Oct 12.

PMID:
18035585
17.

Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas.

Colomiere M, Ward AC, Riley C, Trenerry MK, Cameron-Smith D, Findlay J, Ackland L, Ahmed N.

Br J Cancer. 2009 Jan 13;100(1):134-44. doi: 10.1038/sj.bjc.6604794. Epub 2008 Dec 16.

18.
20.

Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma.

Niwa Y, Kanda H, Shikauchi Y, Saiura A, Matsubara K, Kitagawa T, Yamamoto J, Kubo T, Yoshikawa H.

Oncogene. 2005 Sep 22;24(42):6406-17.

PMID:
16007195

Supplemental Content

Support Center